Authorship in a Digital World - 10/30/2014, Harvard University

Panel discussion on author\u27s rights and copyright in the digital world

Fair Use FAQ

Freqently Asked Questions discussing fair use and what constitutes a transformative or non-transformative use of a work

Understanding Author Addenda with Professor Michael Carroll

Interview with Professor Michael Carroll of American University\u27s Washington College of Law, explaining how addenda can help to modify publishing contracts to help authors retain rights and enable wider use of their works

FAQ: Authorship and Ownership in U.S. Copyright Law

Answers frequently asked questions regarding the relationship between authors and copyright; ownership and management of copyrights; works made for hire; etc

Outcomes, Questions, and Answers: “The Right to Deposit (R2D) Uniform guidance to ensure author compliance and public access”

With the forthcoming release of new federal agency public access plans as a result of the White House Office of Science and Technology Planning (OSTP) public access guidance (“the Nelson memo”), federally-funded authors will face new requirements to deposit their scholarly publications, without an embargo, in agency-designated public access repositories. These requirements will impact authors and their institutions. Federal agencies could improve clarity for authors by adopting the Federal purpose license found in existing federal regulations as a foundation for guidance language and implementation of the Nelson memo. Specifically, the Federal purpose license states that, “The Federal awarding agency reserves a royalty-free, nonexclusive and irrevocable right to reproduce, publish, or otherwise use the work for Federal purposes, and to authorize others to do so

Overview of Understanding Rights Reversion

ASERL Webinar discussing the creation of the guide Understaning Rights Reversion and the responses to it

Recombinant Interleukin-2 in Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia in First Complete Remission

BACKGROUNDRecombinant interleukin-2 (rIL-2) induces cellular cytotoxicity against leukemia blasts. Patients with acute myeloid leukemia (AML) in first complete remission (CR) may harbor minimal residual disease that is susceptible to rIL-2-activated effector cells. METHODSIn the Cancer and Leukemia Group B (CALGB) 19808 study, patients with AML in first CR were randomly assigned after all planned chemotherapy to receive a 90-day course of subcutaneously administered rIL-2 or no further therapy. The primary objective was to compare disease-free survival (DFS) between the 2 treatment arms. A total of 534 patients achieved a CR, 214 of whom were randomized. Six courses of low-dose daily rIL-2 were given for the expansion of cytotoxic effector cells, each followed by 3-day high-dose boluses given to trigger cytotoxicity against minimal residual disease. RESULTSOn the protocol-specified intention-to-treat analysis, the hazards ratio for DFS was 0.75 (95% confidence interval, 0.52-1.09; P=.13); the 5-year DFS rate was 42% in the observation arm and 53% in the rIL-2 treatment arm. The hazards ratio for overall survival (OS) was 0.88 (95% confidence interval, 0.54-1.23; P=.34); the 5-year OS rate was 58% for the observation arm and 63% for the rIL-2 treatment arm. Twenty-five of the 107 patients randomized to treatment with rIL-2 either refused or were unable to initiate therapy and 30 patients did not complete their assigned therapy. However, significant toxicities were not commonly observed. The trial design did not anticipate the difficulties patients would encounter with protocol compliance. CONCLUSIONSThe efficacy of immunotherapy with rIL-2 administered after intensive postremission treatment was not assessed as planned because of unexpected refusals by patients and/or their physicians to comply with protocol-directed therapy. Neither DFS nor OS was found to be significantly improved. Cancer 2014;120:1010-1017. (c) 2013 American Cancer Society. To the authors\u27 knowledge, the current study is the first phase 3 trial of the subcutaneous administration of recombinant interleukin-2 in patients agedmet, important information regarding the use of recombinant interleukin-2 in this setting as well as considerations that may affect the conduct of large phase 3 trials of this nature are presented